For research and educational purposes only. Not medical advice.
Melanotan II Reference
Educational, not medical advice reference for Melanotan II: Skin/Hair; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
Melanotan II pharmacology is broadly characterized in preclinical work, but there is no modern human clinical program supporting tanning / sexual-health / body-composition community claims. Adverse-event reports including priapism and unpredictable pigmentation are documented.
- Categories
- Skin/Hair
- Aliases
- MT-II, α-MSH analog
- Evidence posture
- preclinical — FDA has issued consumer safety communications about melanotan products. Priapism, nausea, unpredictable pigmentation changes, and concerns about melanocytic lesions are commonly reported in adverse-event literature.
- Regulatory status
- No FDA-approved Melanotan II drug label. FDA has issued consumer safety communications about melanotan tanning products, citing unapproved marketing, unknown purity, and documented adverse events. Melanotan II is not the same compound as FDA-approved afamelanotide (Scenesse / Melanotan I).
- Content review status
- research reference